141302-33-2

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-1-PROPYL-1H-PYRAZOLE is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical structure and properties, which contribute to the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
4-BROMO-1-PROPYL-1H-PYRAZOLE is used as a key intermediate in the synthesis of agrochemicals, particularly in the development of new pesticides and plant growth regulators, leveraging its chemical properties to enhance crop protection and yield.
Used in Medicinal Chemistry Research:
4-BROMO-1-PROPYL-1H-PYRAZOLE is utilized as a research compound in medicinal chemistry, where its diverse biological activities and chemical properties are explored for the discovery of novel therapeutic agents and drug candidates.
Used in Chemical Research:
4-BROMO-1-PROPYL-1H-PYRAZOLE serves as a valuable chemical entity in chemical research, where its reactivity, stability, and interactions with other molecules are investigated to understand its potential applications and to develop new synthetic methodologies.

Upstream product

• 2075-45-8 4-bromo-1H-pyrazole 
• 107-08-4 1-iodo-propane 
• 32500-67-7 1-propyl-1H-pyrazole 
• 106-94-5 propyl bromide 

Downstream Products

• 847818-57-9 (1-propyl-1H-pyrazol-4-yl)boronic acid 

Relevant academic research and scientific papers

Crucial role of paramagnetic ligands for magnetostructural anomalies in "breathing crystals"

Breathing crystals based on polymer-chain complexes of Cu(hfac)2 with nitroxides exhibit thermally and light-induced magnetostructural anomalies in many aspects similar to a spin crossover. In the present work, we report the synthesis and investigation of a new family of Cu(hfac)2 complexes with tert-butylpyrazolylnitroxides and their nonradical structural analogues. The complexes with paramagnetic ligands clearly exhibit structural rearrangements in the copper(II) coordination units and accompanying magnetic phenomena characteristic for breathing crystals. Contrary to that, their structural analogues with diamagnetic ligands do not undergo rearrangements in the copper(II) coordination environments. This confirms experimentally the crucial role of paramagnetic ligands and exchange interactions between them and copper(II) ions for the origin of magnetostructural anomalies in this family of molecular magnets.

Synthesis and Evaluation of Pyrazole Derivatives as Potent Antinemic Agents

Pyrazole derivatives were synthesized by bromination of pyrazole, followed by N-alkylation of 4-bromopyrazole. The synthesized derivatives were characterized by microanalytical data and IR and 1H and 13C NMR spectra and were evaluated for their nematicidal activity against the root knot nematode Meloidogyne incognita. The compounds were screened for their egg hatch inhibition and mortality potential, and they showed significant nematicidal activity as compared to the control. 1H-Pyrazol-5(4H)-one was found to be most effective in egg hatch inhibition, and 4-bromopyrazole was found to be most effective in juvenile mortality.

AUTOTAXIN INHIBITOR COMPOUNDS

Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorde

Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility

Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likely source of the TDI signal, and replacement with other bicyclic systems was found to reduce or eliminate the TDI finding. A strategy of reducing the number of aromatic rings and/or lowering c Log D7.4 was then employed to significantly improve aqueous solubility. These efforts culminated in the discovery of 42, a compound with no evidence of TDI, improved aqueous solubility, and robust efficacy in tumor xenograft studies.

CYCLOPROPYL AMIDE DERIVATIVES

The present invention relates to certain cyclopropyl amide compounds, pharmaceutical compositions comprising such compounds, and methods of treating cancer, including leukemias and solid tumors, inflammatory diseases, osteoporosis, atherosclerosis, irritable bowel syndrome, and other diseases and medical conditions, with such compounds and pharmaceutical compositions. The present invention also relates to certain cyclopropyl amide compounds for use in inhibiting nicotinamide phosphoribosyltransferase ("NAMPT").

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl) cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Potent, trans-2-(pyridin-3-yl)cyclopropanecarboxamide-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using fragment-based screening and structure-based design techniques. Multiple crystal structures were obtained of initial fragment leads, and this structural information was utilized to improve the biochemical and cell-based potency of the associated molecules. Many of the optimized compounds exhibited nanomolar antiproliferative activities against human tumor lines in in vitro cell culture experiments. In a key example, a fragment lead (13, KD = 51 μM) was elaborated into a potent NAMPT inhibitor (39, NAMPT IC 50 = 0.0051 μM, A2780 cell culture IC50 = 0.000 49 μM) which demonstrated encouraging in vivo efficacy in an HT-1080 mouse xenograft tumor model.

Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea and amide-containing NAMPT inhibitors. An optimized 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived compound exhibited potent anti-NAMPT activity (18; BC NAMPT IC50 = 11 nM; PC-3 antiproliferative IC50 = 36 nM), satisfactory mouse PK properties, and was efficacious in a PC-3 mouse xenograft model. The crystal structure of another optimized compound (29; NAMPT IC50 = 10 nM; A2780 antiproliferative IC50 = 7 nM) in complex with the NAMPT protein was also determined.

Synthesis of pinacol esters of 1-alkyl-1H-pyrazol-5-yl- and 1-alkyl-1H-pyrazol-4-ylboronic acids

Starting from 1H-pyrazol, a wide number of 1-alkyl-1H-pyrazol-4-yl and 1-alkyl-1H-pyrazol-5-ylboronic acids and their pinacol esters were synthesized and characterized. The key step in the described methodology is the regioselective lithiation of the pyrazole ring. The synthesized pinacolates are stable under prolonged storage and can be used as convenient reagents in organic synthesis.